CollinsA.J., KasiskeB., HerzogC., ChaversB., FoleyR., GilbertsonD.Excerpts from the United States Renal Data System 2006 Annual Data Report.Am J Kidney Dis2007; 49(1 Suppl 1): A6–7, S1–296.
2.
MehrotraR.Peritoneal dialysis penetration in the United States: march toward the fringes?Perit Dial Int2006; 26: 419–22.
3.
LameireN., PeetersP., VanholderR., Van BiesenW.Peritoneal dialysis in Europe: an analysis of its rise and fall.Blood Purif2006; 24: 107–14.
4.
CouchoudC., StengelB., LandaisP., AldigierJ.C., de CornelissenF., DabotC.The Renal Epidemiology and Information Network (REIN): a new registry for end-stage renal disease in France.Nephrol Dial Transplant2006; 21: 411–18.
5.
BenderF.H., BernardiniJ., PirainoB.Prevention of infectious complications in peritoneal dialysis: best demonstrated practices.Kidney Int Suppl2006; 70(1 Suppl 1): S44–54.
6.
HanS.H., LeeS.C., AhnS.V., LeeJ.E., ChoiH.Y., KimB.S.Improving outcome of CAPD: twenty-five years’ experience in a single Korean center.Perit Dial Int2007; 27: 432–40.
7.
BlakeP.G.Peritoneal dialysis in Asia: an external perspective.Perit Dial Int2002; 22: 258–64.
8.
ChanM.K., LamS.S., ChanP.C., ChengI.K.Continuous ambulatory peritoneal dialysis (CAPD): experience with the first 100 patients in a Hong Kong centre.Int J Artif Organs1987; 10: 77–82.
9.
KawaguchiY.National comparisons: optimal peritoneal dialysis outcomes among Japanese patients.Perit Dial Int1999; 19(Suppl 3): S9–16.
BargmanJ.M., ThorpeK.E., ChurchillD.N.; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.J Am Soc Nephrol2001; 12: 2158–62.
12.
ShodaJ., KannoY., SuzukiH.A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.Intern Med2006; 45: 193–8.
13.
LiP.K., ChowK.M., WongT. Y., LeungC.B., SzetoC.C.Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Ann Intern Med2003; 139: 105–12.
14.
WoodrowG.A randomized controlled trial to determine whether treatment with a neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients.Perit Dial Int2006; 26: 113–14.
15.
LobbedezT., GardamM., DedierH., BurdzyD., ChuM., IzattS.Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.Nephrol Dial Transplant2004; 19: 3140–3.
16.
PrakashanK.P., AnnigeriR.A., ChuM., BargmanJ.M., VasS.I., OreopoulosD.G.Local application of mupirocin at the peritoneal catheter exit site prevents early postoperative infections and should become standard practice.Perit Dial Int2001; 21: 526–7.
WilliamsJ.D., CraigK.J., von RuhlandC., TopleyN., WilliamsG.T.; Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis.Kidney Int Suppl2003; 88: S43–9.
19.
ChinA.I., YeunJ.Y.Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis.Am J Kidney Dis2006; 47: 697–712.
20.
AhmadM., ShahH., PliakogiannisT., OreopoulosD.G.Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.Int Urol Nephrol2007; 39: 299–312.
21.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.; Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
22.
GarciaH., Hernandez-JarasJ., del Carmen CruzM., AgramuntI., CalvoC., CerrilloV.Short- and medium-term increase of CA125 in peritoneal effluent using a neutral-pH solution.Perit Dial Int2003; 23: 375–80.
23.
LeeH.Y., ChoiH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R.Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.Nephrol Dial Transplant2006; 21: 2893–9.
24.
BargmanJ.M.Peritoneal dialysis solutions and patient survival: does wishing make it so?Nephrol Dial Transplant2006; 21: 2684–6.
25.
DaviesS.J.Exploring new evidence of the clinical benefits of icodextrin solutions.Nephrol Dial Transplant2006; 21(Suppl 2): ii47–50.
26.
CharestA.F., MendelssohnD.C.Are North American nephrologists biased against peritoneal dialysis?Perit Dial Int2001; 21: 335–7.
27.
JassalS.V., KrishnaG., MallickN.P., MendelssohnD.C.Attitudes of British Isles nephrologists towards dialysis modality selection: a questionnaire study.Nephrol Dial Transplant2002; 17: 474–7.
